Otsuka, a global leader in mental health, nephrology and digital innovation, today released its first-ever impact report.
Otsuka’s Economic and Health Impact in the United States highlights the contributions of Otsuka’s U.S. pharmaceutical subsidiaries — Otsuka America Pharmaceutical, Inc. (OAPI) and Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Collectively, the subsidiaries comprise nearly 2,000 employees at three corporate offices and other locations in the United States working in all aspects of bringing new medicines to market, from research and development to commercialization.
“We’re driven by a commitment to creating new products for better health worldwide. Our employees are at the helm of this mission and the patients we humbly serve are at the core,” said Kabir Nath, Senior Managing Director, Global Pharmaceutical Business, Otsuka.
The report outlines Otsuka’s work to improve clinical outcomes for patients and the company’s strong commitment to the community in four priority areas: Mental Health Care Equity, Addressing Social Determinants of Health, Care Disparities in Nephrology and Access to Digital Health Solutions.
Otsuka’s Economic and Health Impact in the United States also details Otsuka’s direct positive impact on the economy via high-quality jobs, tax revenues, and economic output, and indirect support of additional jobs and economic activity.
Economic Impact Highlights
The economic impact analysis presented in the report is based on Otsuka’s 2020 U.S. payroll and operating expenses and shows Otsuka supported nearly 11,000 US jobs, generated more than $880 million in labor income (a measure of wages), and contributed $3.3 billion in economic output.
Otsuka also supports tax revenue in the United States. In 2020, tax receipts attributable to or supported by Otsuka’s economic activity totaled nearly $300 million.
Otsuka’s commitment to finding solutions for unmet medical needs is reflected in its pipeline. The company has therapeutics in all stages of development in nephrology, central nervous system (CNS) disorders, and other areas such as hospitalized influenza, multidrug-resistant tuberculosis, and Crohn’s disease. As of March 2022, Otsuka is conducting four Phase 1 trials, two Phase 2 trials, and 12 Phase 3 trials.
Details on Otsuka’s patient advocacy and support efforts, as well as its affiliates and alliances can be found in the full version of the report, which can be downloaded here.